Pembrolizumab for the first-line treatment of non-small cell lung cancer-Reference-Cited by-同舟云学术

Pembrolizumab for the first-line treatment of non-small cell lung cancer

Published:2018-09-19 Issue:10 Volume:18 Page:1015-1021
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Ninomiya Kiichiro¹,Hotta Katsuyuki²

Affiliation:

1. Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

2. Center of Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2018.1522300

Reference55 articles.

1. Mechanistic and pharmacologic insights on immune checkpoint inhibitors

2. Elements of cancer immunity and the cancer–immune set point

3. Mechanism of Action of Immunotherapy

4. Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

5. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis;Frontiers in Immunology;2024-07-11

2. Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models;Cancer Immunology, Immunotherapy;2024-06-04

3. MB2033, an anti-PD-L1 × IL-2 variant fusion protein, demonstrates robust anti-tumor efficacy with minimal peripheral toxicity;Cancer Immunology, Immunotherapy;2024-06-04

4. Clinical Characteristics and Outcomes of Pembrolizumab Induced Gastritis: A Systematic Review of the Literature;Journal of Gastrointestinal Cancer;2024-05-24

5. Engineering PD-1-targeted small protein variants for in vitro diagnostics and in vivo PET imaging;Journal of Translational Medicine;2024-05-06